Logo
x

Search

Subscribe Now

 EMA

Rhythm Pharmaceuticals Reports Topline Data from P-III (TRANSCEND) Trial of Setmelanotide for Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals Reports Topline Data from P-III (TRANSCEND) Trial of Setmelanotide for Acquired Hypothalamic Obesity

  • April 8, 2025
Averoa Receives the CHMP’s Positive Opinion for Xoanacyl to Treat Chronic Kidney Disease

Averoa Receives the CHMP’s Positive Opinion for Xoanacyl to Treat Chronic Kidney Disease

  • April 2, 2025
Crinetics Pharmaceuticals Reports the EMA’s Acceptance of Paltusotine for Acromegaly

Crinetics Pharmaceuticals Reports the EMA’s Acceptance of Paltusotine for Acromegaly

  • March 31, 2025
Merck Presents P-III (3475A-D77) Trial Data of SC Keytruda for NSCLC at ELCC 2025

Merck Presents P-III (3475A-D77) Trial Data of SC Keytruda for NSCLC at ELCC 2025

  • March 28, 2025
Ionis Partners with Sobi for Olezarsen to Treat Familial Chylomicronemia Syndrome (FCS) & Severely Elevated Triglycerides

Ionis Partners with Sobi for Olezarsen to Treat Familial Chylomicronemia Syndrome (FCS) & Severely Elevated Triglycerides

  • March 27, 2025
New Drug Designations - February 2025

New Drug Designations - February 2025

  • March 25, 2025
Sanofi Reports the US FDA’s Acceptance & Priority Review of Tolebrutinib for Non-Relapsing Secondary Progressive Multiple Sclerosis

    Sanofi Reports the US FDA’s Acceptance & Priority Review of Tolebrutinib for Non-Relapsing Secondary Progressive Multiple Sclerosi...

    • March 25, 2025
    GSK Reports the EMA’s Acceptance of Nucala (Mepolizumab) as an Add-on Treatment for COPD

      GSK Reports the EMA’s Acceptance of Nucala (Mepolizumab) as an Add-on Treatment for COPD

      • March 24, 2025
      Alnylam Pharmaceuticals Reports the US FDA’s Approval of Amvuttra (Vutrisiran) to Treat ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

        Alnylam Pharmaceuticals Reports the US FDA’s Approval of Amvuttra (Vutrisiran) to Treat ATTR Amyloidosis with Cardiomyopathy (ATTR...

        • March 21, 2025
        Biocon Biologics Report the P-III Study Positive Results of Yesintek (Biosimilar, Stelara)

          Biocon Biologics Report the P-III Study Positive Results of Yesintek (Biosimilar, Stelara)

          • March 7, 2025
          New Drug Designations - January 2025

            New Drug Designations - January 2025

            • February 28, 2025
            Bayer Submits MAA of Finerenone to the EMA for Heart Failure (HF)

              Bayer Submits MAA of Finerenone to the EMA for Heart Failure (HF)

              • February 4, 2025
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.